Domainex, a drug discovery and integrated medicines research partner, opens a new biology centre to further support collaborations with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally.
The opening was officiated by Mrs Julie Spence OBE CStJ QPM, HM Lord-Lieutenant of Cambridgeshire, who also presented the King’s Award for Enterprise: International Trade 2023 to Domainex’s CEO, Dr Tom Mander.
Approximately, 50 guests, including senior executives from leading biotechnology companies and local dignitaries, attended the opening event and were offered guided tours of the facility.
The building, based at the Unity Campus at Pampisford, is located in a fast-growing Cambridge hub for life-science innovation with excellent transport links.
It provides a more than three-fold increase on the previous footprint to allow continued expansion of people and equipment to support Domainex’s global business growth.
The facility will be able to house more than 100 scientists including biochemists, biophysicists, cell biologists, protein scientists, bioanalysts and structural biologists. With the existing chemistry centre at Chesterford Research Park, the combined footprint of Domainex’s research facilities in the Cambridge life science hub now exceeds 44,000 sqft.
Dr Tom Mander, CEO of Domainex, commented: “Our exciting new facility will enable us to continue to expand the range of our services and will help bring much needed treatments to patients faster and more effectively.”
